Analysts split on Amylin's Byetta
Sanofi aventis' Acomplia -- if it wins FDA approval -- could also impact Byetta. Sanofi is seeking an obesity indication for the drug, but if it gets approved for type 2 diabetes, it could steal some share from Byetta because it too offers the advantage of weight loss.
Read the rest of this entry ... (52 words left)
